Standard BioTools/$LAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Standard BioTools
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Ticker
$LAB
Sector
Primary listing
Employees
387
Headquarters
Website
LAB Metrics
BasicAdvanced
$316m
3.98
$0.20
1.38
-
Price and volume
Market cap
$316m
Beta
1.38
52-week high
$1.72
52-week low
$0.79
Average daily volume
3.1m
Financial strength
Current ratio
12.356
Quick ratio
11.772
Long term debt to equity
4.268
Total debt to equity
5.256
Interest coverage (TTM)
-3,019.46%
Profitability
EBITDA (TTM)
-70.292
Gross margin (TTM)
49.62%
Net profit margin (TTM)
90.67%
Operating margin (TTM)
-91.02%
Effective tax rate (TTM)
42.98%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-8.05%
Return on equity (TTM)
-9.86%
Valuation
Price to earnings (TTM)
3.979
Price to revenue (TTM)
3.608
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-3.294
Free cash flow yield (TTM)
-30.36%
Free cash flow per share (TTM)
-0.246
Growth
Revenue change (TTM)
-50.14%
Earnings per share change (TTM)
-157.40%
3-year revenue growth (CAGR)
-3.69%
10-year revenue growth (CAGR)
-3.00%
3-year earnings per share growth (CAGR)
-50.29%
10-year earnings per share growth (CAGR)
-20.38%
What the Analysts think about LAB
Analyst ratings (Buy, Hold, Sell) for Standard BioTools stock.
LAB Financial Performance
Revenues and expenses
LAB Earnings Performance
Company profitability
LAB News
AllArticlesVideos
LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers
Business Wire·1 day ago
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders
Business Wire·3 days ago
Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects
Newsfile Corp·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs